Navigation Links
Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs
Date:11/5/2008

. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include full-year net loss and net cash burn projections, as well as statements about the company's pandemic influenza and CMV vaccine programs, the company's Vaxfectin(R) adjuvant, and other independent and collaborative programs. Risks and uncertainties include whether Vical or others will continue development of the CMV vaccine, the pandemic influenza vaccine, the Vaxfectin(R) adjuvant, or any other independent or collaborative programs; whether Vical will announce results of the Phase 2 CMV vaccine interim analysis in the fourth quarter, if at all; whether Vical will be able to complete a mutually satisfactory definitive agreement with AnGes; whether preliminary H5N1 DNA vaccine Phase 1 clinical trial results will be confirmed upon further analysis or in larger studies; whether Vaxfectin(R) or other results in animal studies can be duplicated in human clinical trials; whether nonclinical results will advance to human clinical testing, and if so, whether such testing will be successful; whether commercial partners or collaborators will pursue additional Vaxfectin(R) applications; whether the company will achieve levels of revenues and control expenses to meet projected financial performance; whether any product candidates will be shown to be safe and efficacious in clinical trials; the timing of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; the dependence of the company on its col
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vical Announces News Release and Conference Call Schedule For Third Quarter 2008 Financial Results
2. Vical to Present at Upcoming Investor Conferences
3. Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device
4. Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
5. Vical to Present at UBS Global Life Sciences Conference
6. Society of Gynecologic Oncologists to Host Cervical Cancer Prevention Forum
7. Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System
8. Vical to Present at Upcoming Investor Conferences
9. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
10. Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results
11. One4One Campaign to Raise $1 Million to Improve Cervical Cancer Education and Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... San Francisco, California (PRWEB) October 01, 2014 ... grant from the National Science Foundation to expand their ... approaches to build and modify DNA. The Small Business ... help commercialize the “j5” technology under exclusive license from ... the Joint BioEnergy Institute , an LBNL laboratory ...
(Date:9/30/2014)... 2014 Applying a well-known optical phenomenon called ... University has demonstrated the ability to "paint" ultra-thin ... holds promise for making future, flexible electronic devices, ... of next-gen rocket ships and spacecraft with extremely ... oil in water, it becomes iridescent, revealing a ...
(Date:9/30/2014)... 30, 2014 Shimadzu Scientific Instruments ... easy-to-use and highly precise tool for measuring displacement ... elongation. With 1000-mm maximum movement distance, the DSES-1000 ... a gauge length of 10 mm. In addition, ... above 50-mm stroke and within +/- 100 µm ...
(Date:9/30/2014)... 30, 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ... has received a Canadian Patent for Inhibition or ... patent includes claims using thymosin beta 4, various ... for these purposes.  The patent will expire in ... ( www.regenerx.com ) RegeneRx is ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... Ind. - Researchers are edging toward the creation ... of ultra-efficient transmission of light, with potential applications ... The metamaterial - layers of silver and titanium ... dramatically changes the properties of light. The light ...
... CRANBURY, N.J., May 25, 2012  Oncobiologics, Inc. announced ... positions with established biopharmaceutical industry experts. Stephen J. ... and Vincent J. Benn, Ph.D. has joined the ... The company also announced its new Scientific Advisory ...
... ANAHEIM, Calif., May 24, 2012 Questcor Pharmaceuticals, Inc. (NASDAQ: ... present at the Jefferies 2012 Global Healthcare Conference in New ... 8:00 a.m. ET. A live webcast and subsequent ... http://ir.questcor.com/events.cfm .  The replay will be available for approximately 90 ...
Cached Biology Technology:'Metamaterials,' quantum dots show promise for new technologies 2Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory Board 2Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory Board 3Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference 2
(Date:9/30/2014)... the environmental effects of moorland burning is published today ... with the aim of relieving tensions on both sides ... EMBER (Effects of Moorland Burning on the Ecohydrology of ... moorland, which is practised predominantly to support red grouse ... peat hydrology, peat chemistry and physical properties, river water ...
(Date:9/30/2014)... The most comprehensive assessment conducted by the Ocean ... out of 100 in overall health. In addition, ... Antarctic and the 15 ocean regions beyond national ... maintaining a healthy climate, safeguarding biodiversity and providing ... update of the index, a partnership led by ...
(Date:9/30/2014)... Calif. The National Institutes of Health (NIH) ... today to develop an electrode array system that ... brain works through unprecedented resolution and scale. , ... to support President Obama,s BRAIN (Brain Research ... research effort to revolutionize our understanding of the ...
Breaking Biology News(10 mins):Grouse moor burning causes widespread environmental changes 2Rating the planet's oceans 2Rating the planet's oceans 3NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3
... (ODS) at the National Institutes of Health (NIH) announces ... Bibliography of Significant Advances in Dietary Supplement Research. The ... by government, industry, and academic institutions, as well as ... of laboratory, human studies, and observational studies in the ...
... powerful antioxidant in green tea may prevent or delay ... Georgia researchers say. Researchers were testing EGCG, green ... 1 diabetes and primary Sjogren,s syndrome, which damages moisture-producing ... study focused on Sjogren,s syndrome, so learning that EGCG ...
... Washington, DCGeorgetown University Medical Center and Oak ... between the institutions that formalizes their research ... researchparticularly in the areas of structural biology, ... biology. The Comprehensive Research and Development ...
Cached Biology News:Annual Bibliography of Significant Advances in Dietary Supplement Research 2007 2Green tea may delay onset of type 1 diabetes 2Green tea may delay onset of type 1 diabetes 3GUMC and Oak Ridge National Labs announce unique research partnership 2GUMC and Oak Ridge National Labs announce unique research partnership 3
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
... Anti-Natural Killer Cell Receptor-P1, clone ... Hybridoma produced by ... BALB/c mice immunized (BALB/c X ... cells and mouse myeloma cellline. ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Biology Products: